Fluorouracil Therapy for Proliferative Vitreoretinopathy after Vitrectomy
References (19)
- et al.
Epiretinal membrane formation after vitrectomy
Am. J. Ophthalmol.
(1982) - et al.
A new concept for vitreous surgery. 3. Indications and results
Am. J. Ophthalmol.
(1972) - et al.
A logical approach to the treatment of massive periretinal proliferation
Trans. Am. Acad. Ophthalmol. Otolaryngol.
(1978) - et al.
Inhibition of intraocular proliferations with intravitreal corticosteroids
Am. J. Ophthalmol.
(1980) - et al.
Glucocorticosteroid inhibition of intraocular proliferation after injury
Am. J. Ophthalmol.
(1981) - et al.
Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide
Am. J. Ophthalmol.
(1980) - et al.
The effect of penicillamine on posttraumatic vitreous proliferation
Am. J. Ophthalmol.
(1981) - et al.
Ocular toxicity of fluorouracil after vitrectomy
Am. J. Ophthalmol.
(1983) - et al.
Fluorouracil for the treatment of massive periretinal proliferation
Am. J. Ophthalmol.
(1982)
Cited by (85)
Proliferative vitreoretinopathy: Prophylactic treatment
2014, Journal Francais d'OphtalmologieGold nanoparticles downregulate VEGF-and IL-1β-induced cell proliferation through Src kinase in retinal pigment epithelial cells
2010, Experimental Eye ResearchCitation Excerpt :Blocking the effects of these two factors (VEGF and IL-1β) may therefore be a potential strategy for treatment of PVR. Recent studies suggest that the pharmacological agents such as 5-fluorouracil (Stern et al., 1983; Blankenship, 1989), daunorubicin (Khawly et al., 1991), retinoids (Araiz et al., 1993), 20-benzoyloxycinnamaldehyde (Lee et al., 2002), alkylphosphocholines (Eibl et al., 2006) are used as effective drugs for the treatment of PVR besides surgery. In the current scenario, several nanoparticles have been suggested as a drug for treatment of various diseases including ocular disorders.
Proliferative Vitreoretinopathy
2005, Retina: Fourth EditionVitreoretinal Interface
2005, Retina: Fourth EditionThe Mechanism of Action of Drugs for The Treatment of Vitreoretinal Scarring
2005, Retina: Fourth EditionPharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy
2004, Journal Francais d'Ophtalmologie
This study was supported by research grants EY03228 (Dr. Stern), EY02082 (Dr. Anderson), and EY00888 (Dr. Fisher) from the National Eye Institute, Research Career Development Award EY00174 from the National Institutes of Health (Dr. Fisher), and by the Veterans Administration.
Reprint requests to Walter H. Stern, M.D., 4150 Clement St., San Francisco, CA 94121.